BioNTech SE
22UA
株式のランク
#993
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
株価
$94.89
最終同期: 2026-10-20
時価総額
$23.84B
変化（1日）
1.65%
変化（1年）
-11.37%
国
DE
取引 BioNTech SE (22UA)
カテゴリー
Healthcare
BioNTech SE（22UA）のP/E比率
October 2026 時点のP/E比率 TTM -11.72
BioNTech SE の最新の財務報告および株価によると、現在の P/E (TTM) は -11.72 です。2023 年末時点での P/E は 24.57 でした。
BioNTech SE の P/E 比率の履歴（2016 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -11.72 | -70.17% |
| 2024 | -39.28 | -259.83% |
| 2023 | 24.57 | 566.38% |
| 2022 | 3.69 | -27.41% |
| 2021 | 5.08 | -99.55% |
| 2020 | 1.13K | -3,248.09% |
| 2019 | -35.91 | -41.40% |
| 2018 | -61.28 | 78.37% |
| 2017 | -34.35 | 0.00% |
| 2016 | 0.00 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -345.61% |
US
|
|
| -28.36 | 142.00% |
US
|
|
| -24.57 | 109.64% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -358.82% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。